PPARA and metabolic dysfunction-associated steatohepatitis: The dual PPARα/δ agonist elafibranor (GFT505) improved glycemic and lipid metabolism in NASH patients in a phase II clinical trial, reduced liver inflammation and did not exacerbate fibrosis, demonstrating good tolerability.